![]() | |
Names | |
---|---|
IUPAC name
6-[1-Hydroxy-2-[(2-methyl-4-phenylbutan-2-yl)amino]ethyl]-3,4-dihydro-1H-quinolin-2-one
| |
Other names
Brefanolol
| |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C22H28N2O2 | |
Molar mass | 352.478 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Brefonalol is a beta-adrenergic antagonist that reduces heart frequency and blood pressure and dilates blood vessels. It has been studied in around 1990,[1] but is not known to be marketed as of 2021[update].
References
[edit]- ^ Halabi, A; Endell, W; Halabi, I; Kirch, W (1990). "Hemodynamic effects of brefanolol and propranolol assessed by noninvasive methods in patients with arterial hypertension". Journal of Cardiovascular Pharmacology. 16 (1): 81–6. doi:10.1097/00005344-199007000-00011. PMID 1696669. S2CID 41692901.